Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 13/20 | 0.67 |
| ▸ | STK4 | Q13043 | 12/20 | 0.67 |
| ▸ | STK3 | Q13188 | 12/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301835 | 0.82 | STK4 (0.66) | LRRK2STK4STK3ALDH1A1HPGD | |
| SCHEMBL15401357 | 0.80 | LRRK2 (1.00) | LRRK2STK4STK3 | |
| SCHEMBL31301551 | 0.79 | LMNA (0.74) | LRRK2STK4STK3ALDH1A1HPGD | |
| SCHEMBL31301658 | 0.78 | STK4 (0.63) | LRRK2STK4STK3ALDH1A1CNR2 | |
| SCHEMBL30295803 | 0.77 | RIPK1 (0.49) | LRRK2STK4STK3 | |
| SCHEMBL30295802 | 0.74 | LRRK2 (0.67) | LRRK2STK4STK3CNR2PDE10A | |
| SCHEMBL30295705 | 0.72 | LRRK2 (0.71) | LRRK2STK4STK3 | |
| SCHEMBL31301676 | 0.70 | LRRK2 (0.93) | LRRK2STK4STK3 | |
| SCHEMBL31301604 | 0.70 | LRRK2 (0.98) | LRRK2STK4STK3 | |
| SCHEMBL20319865 | 0.70 | STK4 (0.53) | LRRK2STK4STK3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2025-02-13 | — | — | US | disclosed |
| WO-2023055731-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051337-A1 | INHIBITORS OF SERINE/THREONINE PROTEIN KINASE STK3 OR STK4 AND USES THEREOF | STK3, STK4, STK36 | LRRK2 210/4885STK4 2/4885STK3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.